tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CGTX Stock Latest News

Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment
The FlyCognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment
1d ago
CGTX
Cognition Therapeutics Announces $30.1M Direct Offering
PremiumCompany Announcements
Cognition Therapeutics Announces $30.1M Direct Offering
7d ago
8K
CGTX
Cognition Therapeutics announces $30M registered direct offering of common stock
PremiumThe Fly
Cognition Therapeutics announces $30M registered direct offering of common stock
7d ago
CGTX
Cognition Therapeutics Regains Nasdaq Compliance
PremiumCompany Announcements
Cognition Therapeutics Regains Nasdaq Compliance
9d ago
8K
CGTX
Cognition Therapeutics regains compliance with Nasdaq
PremiumThe Fly
Cognition Therapeutics regains compliance with Nasdaq
9d ago
CGTX
Cognition Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsCognition Therapeutics Reports Q2 2025 Financial Results
20d ago
CGTX
Cognition Therapeutics confirms aligment with FDA on path for zervimesine
Premium
The Fly
Cognition Therapeutics confirms aligment with FDA on path for zervimesine
23d ago
CGTX
Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics
Premium
Ratings
Promising Developments and Regulatory Milestones Drive Buy Rating for Cognition Therapeutics
24d ago
CGTX
Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)
PremiumThe Fly
Cognition Therapeutics reports Q2 EPS (11c), consensus (10c)
28d ago
CGTX
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors
PremiumCompany Announcements
Cognition Therapeutics’ Expanded Access Program for CT1812: A Promising Update for Investors
1M ago
CGTX
Cognition Therapeutics presents data at AAIC on CT1812 in dementia
PremiumThe Fly
Cognition Therapeutics presents data at AAIC on CT1812 in dementia
1M ago
CGTX
Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study
PremiumThe Fly
Cognition Therapeutics publishes results of analysis from Phase 2 SEQUEL study
1M ago
CGTX
Cognition Therapeutics ot present data from zervimesine Phase 2 study
PremiumThe FlyCognition Therapeutics ot present data from zervimesine Phase 2 study
2M ago
CGTX
Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine
Premium
Ratings
Cognition Therapeutics Receives Buy Rating Amid Promising Developments and Regulatory Advancements for Zervimesine
2M ago
CGTX
Cognition completes End-of-Phase 2 meeting with FDA for zervimesine
Premium
The Fly
Cognition completes End-of-Phase 2 meeting with FDA for zervimesine
2M ago
CGTX
Cognition Therapeutics’ Promising Clinical Progress and Regulatory Advancements Justify Buy Rating
PremiumRatings
Cognition Therapeutics’ Promising Clinical Progress and Regulatory Advancements Justify Buy Rating
2M ago
CGTX
Cognition Therapeutics announces Phase 2 ‘START’ study surpassed 50% enrollment
PremiumThe Fly
Cognition Therapeutics announces Phase 2 ‘START’ study surpassed 50% enrollment
2M ago
CGTX
Cognition Therapeutics Advances with CT1812 in Dementia Study
PremiumCompany Announcements
Cognition Therapeutics Advances with CT1812 in Dementia Study
2M ago
CGTX
Cognition to conduct end-of-Phase 2 meeting with FDA on zervimesine
PremiumThe Fly
Cognition to conduct end-of-Phase 2 meeting with FDA on zervimesine
2M ago
CGTX
Cognition Therapeutics Holds Virtual Annual Stockholders Meeting
PremiumCompany AnnouncementsCognition Therapeutics Holds Virtual Annual Stockholders Meeting
3M ago
8K
CGTX
Cognition Therapeutics: Buy Rating Affirmed on Non-Dilutive Funding and Regulatory Progress for Zervimesine
Premium
Ratings
Cognition Therapeutics: Buy Rating Affirmed on Non-Dilutive Funding and Regulatory Progress for Zervimesine
3M ago
CGTX
Cognition Therapeutics Launches Expanded Access Program for Zervimesine
Premium
Company Announcements
Cognition Therapeutics Launches Expanded Access Program for Zervimesine
3M ago
8K
CGTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >